PMDA drug package insert
イムネース注35
PMDA Prescription drug · 共和薬品工業株式会社 · package insert Apr 1, 2024
Key facts
| Brand names | イムネース注35 |
|---|---|
| Nonproprietary names | テセロイキン（遺伝子組換え） |
| Companies | 製造販売元／共和薬品工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 遺伝子組換え型インターロイキン－2製剤 |
| Therapeutic category codes | 876399 |
| YJ codes | 6399411D1022 |
| Approval numbers | 20400AMZ00789 |
| Package insert edition | 第5版 |
| Package insert date | Apr 1, 2024 |
| PMDA document key | 672173_6399411D1022_2 |
| PMDA company code | 672173 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: